SE0301906D0 - New compounds - Google Patents

New compounds

Info

Publication number
SE0301906D0
SE0301906D0 SE0301906A SE0301906A SE0301906D0 SE 0301906 D0 SE0301906 D0 SE 0301906D0 SE 0301906 A SE0301906 A SE 0301906A SE 0301906 A SE0301906 A SE 0301906A SE 0301906 D0 SE0301906 D0 SE 0301906D0
Authority
SE
Sweden
Prior art keywords
hydrogen
new compounds
nhar
nitro
halogen
Prior art date
Application number
SE0301906A
Other languages
Swedish (sv)
Inventor
Rhonan Ford
Frederic Leroux
Michael Stocks
Britt-Marie Swahn
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Priority to SE0301906A priority Critical patent/SE0301906D0/en
Publication of SE0301906D0 publication Critical patent/SE0301906D0/en
Priority to PCT/SE2004/001015 priority patent/WO2004113303A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pulmonology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

The present invention relates to new compounds of formula (I) in which:X is CR<4> or N; R<1> is -OR<5>, -NHCOR<6> or -NR<6>R<7>; R<2 >is hydrogen, Oar<1> or -NHAr<1> wherein Ar<1> is aryl optionally substituted with one or more of R<8>, -OR<8>, -NR<8>R<9>, -CONR<8>R<9>, -COOR<8>, -NR<8>COR<9>, -SR<8>, -SO2NR<8>R<9>, -NR<8>SO2 R<9>, halogen, cyano, or nitro; R<3> is hydrogen or -NHAr<2> wherein Ar<2> is benzene optionally substituted with one or more of R<8>, -OR<8>, -NR<8>R<9>, halogen or nitro, wherein R<2> and R<3> is not simultaneously hydrogen; a process for their preparation and new intermediates used therein, pharmaceutical formulations containing said therapeutically active compounds and to the use of said active compounds in therapy.
SE0301906A 2003-06-26 2003-06-26 New compounds SE0301906D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
SE0301906A SE0301906D0 (en) 2003-06-26 2003-06-26 New compounds
PCT/SE2004/001015 WO2004113303A1 (en) 2003-06-26 2004-06-23 INDAZOLE/PYRZOLO[4,3-c]PYRIDIN DERIVATIVES AS JNK INHIBITORS, COMPOSITIONS AND METHODS RELATED THERETO AS WELL AS INTERMEDIATE THEREOF

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0301906A SE0301906D0 (en) 2003-06-26 2003-06-26 New compounds

Publications (1)

Publication Number Publication Date
SE0301906D0 true SE0301906D0 (en) 2003-06-26

Family

ID=27656639

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0301906A SE0301906D0 (en) 2003-06-26 2003-06-26 New compounds

Country Status (2)

Country Link
SE (1) SE0301906D0 (en)
WO (1) WO2004113303A1 (en)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7135575B2 (en) 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
AU2004218463B2 (en) * 2003-03-03 2009-07-16 Array Biopharma, Inc. p38 inhibitors and methods of use thereof
DE102004028862A1 (en) * 2004-06-15 2005-12-29 Merck Patent Gmbh 3-aminoindazoles
CA2619365A1 (en) * 2005-08-22 2007-03-01 Amgen Inc. Pyrazolopyridine and pyrazolopyrimidine compounds useful as kinase enzymes modulators
AU2006283940A1 (en) 2005-08-25 2007-03-01 F. Hoffmann-La Roche Ag P38 MAP kinase inhibitors and methods for using the same
ES2379656T3 (en) 2006-01-31 2012-04-30 Array Biopharma, Inc. Kinase inhibitors and procedures for their use
WO2008074676A1 (en) 2006-12-19 2008-06-26 F. Hoffmann-La Roche Ag Pyrazolo [3, 4 -d] pyrimidine p38 map kinase inhibitors
AR071780A1 (en) * 2008-05-15 2010-07-14 Nerviano Medical Sciences Srl BICYCLE CARBONILAMINO-PIRAZOLES CARBAMILILE DERIVATIVES AS PROFARMACOS
EP2789614B1 (en) 2009-08-11 2017-04-26 Bristol-Myers Squibb Company Azaindazoles as Btk kinase modulators and use thereof
EP2937345B1 (en) 2009-12-29 2018-03-21 Dana-Farber Cancer Institute, Inc. Type ii raf kinase inhibitors
JP2013522292A (en) * 2010-03-16 2013-06-13 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド Indazole compounds and their use
EP2822935B1 (en) 2011-11-17 2019-05-15 Dana-Farber Cancer Institute, Inc. Inhibitors of c-jun-n-terminal kinase (jnk)
EP2689779A1 (en) 2012-07-27 2014-01-29 Pierre Fabre Medicament Derivatives of azaindazole or diazaindazole type for treating a cancer overexpressing trk
EP2689778A1 (en) 2012-07-27 2014-01-29 Pierre Fabre Medicament Derivatives of azaindoles or diazaindoles for treating pain
WO2014063068A1 (en) 2012-10-18 2014-04-24 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
US9758522B2 (en) 2012-10-19 2017-09-12 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged small molecules as inducers of protein degradation
US10000483B2 (en) 2012-10-19 2018-06-19 Dana-Farber Cancer Institute, Inc. Bone marrow on X chromosome kinase (BMX) inhibitors and uses thereof
SG11201502884TA (en) * 2012-11-08 2015-05-28 Pfizer Heteroaromatic compounds as dopamine d1 ligands
ES2784454T3 (en) 2013-09-09 2020-09-25 Peloton Therapeutics Inc Aryl ethers and their uses
AU2014337044A1 (en) 2013-10-18 2016-05-05 Dana-Farber Cancer Institute, Inc. Polycyclic inhibitors of cyclin-dependent kinase 7 (CDK7)
ES2676734T3 (en) 2013-10-18 2018-07-24 Syros Pharmaceuticals, Inc. Heteroatomic compounds useful for the treatment of proliferative diseases
US9862688B2 (en) 2014-04-23 2018-01-09 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged janus kinase inhibitors and uses thereof
US10017477B2 (en) 2014-04-23 2018-07-10 Dana-Farber Cancer Institute, Inc. Janus kinase inhibitors and uses thereof
US10336707B2 (en) 2014-12-16 2019-07-02 Eudendron S.R.L. Heterocyclic derivatives modulating activity of certain protein kinases
EP3236959A4 (en) 2014-12-23 2018-04-25 Dana Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
WO2016144825A1 (en) 2015-03-11 2016-09-15 Peloton Therapeutics, Inc. Aromatic compounds and uses thereof
WO2016145045A1 (en) 2015-03-11 2016-09-15 Peloton Therapeutics, Inc. Compositions for use in treating glioblastoma
US10155726B2 (en) 2015-03-11 2018-12-18 Peloton Therapeutics, Inc. Substituted pyridines and uses thereof
US10278942B2 (en) 2015-03-11 2019-05-07 Peloton Therapeutics, Inc. Compositions for use in treating pulmonary arterial hypertension
CA2978518C (en) 2015-03-27 2023-11-21 Nathanael S. Gray Inhibitors of cyclin-dependent kinases
WO2016168510A1 (en) 2015-04-17 2016-10-20 Peloton Therapeutics, Inc. Combination therapy of a hif-2-alpha inhibitor and an immunotherapeutic agent and uses thereof
AU2016276963C1 (en) 2015-06-12 2021-08-05 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
WO2017044858A2 (en) 2015-09-09 2017-03-16 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
WO2017127371A1 (en) * 2016-01-21 2017-07-27 Sunnylife Pharma Inc. Bruton's tyrosine kinase inhibitors
US10793566B2 (en) 2016-01-21 2020-10-06 Zibo Biopolar Changsheng Pharmaceutical Co. Ltd. Bruton's tyrosine kinase inhibitors
JP6972002B2 (en) 2016-03-11 2021-11-24 エンジェル・ファーマシューティカル・カンパニー・リミテッド Compounds and methods for regulating Bruton's tyrosine kinase
EP3725777A1 (en) * 2019-04-17 2020-10-21 Rottapharm Biotech S.r.l. Benzo- and pyrido-pyrazoles as protein kinase inhibitors
WO2021075476A1 (en) * 2019-10-18 2021-04-22 武田薬品工業株式会社 Heterocyclic compound

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1025102B1 (en) * 1997-10-20 2004-05-19 F. Hoffmann-La Roche Ag Bicyclic kinase inhibitors
US6897231B2 (en) * 2000-07-31 2005-05-24 Signal Pharmaceuticals, Inc. Indazole derivatives as JNK inhibitors and compositions and methods related thereto
PE20020506A1 (en) * 2000-08-22 2002-07-09 Glaxo Group Ltd PIRAZOLE DERIVATIVES FUSED AS PROTEIN KINASE INHIBITORS
US6982274B2 (en) * 2001-04-16 2006-01-03 Eisai Co., Ltd. 1H-indazole compound
TW200302722A (en) * 2002-02-13 2003-08-16 Astrazeneca Ab Therapeutic agents

Also Published As

Publication number Publication date
WO2004113303A1 (en) 2004-12-29

Similar Documents

Publication Publication Date Title
SE0301906D0 (en) New compounds
ES2145922T3 (en) USEFUL SPYRO-AZABICYCLIC COMPOUNDS IN THERAPY.
AR034259A1 (en) POLYMORPHES OF AN EPOTILONE ANALOG, PROCESSES TO PREPARE THEM AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
DE68919010D1 (en) Purine compounds, processes for their preparation and pharmaceutical preparations.
ES2122076T3 (en) DERIVATIVES OF NOR-BILIAR ACIDS, PROCEDURE FOR THE PREPARATION AND USE OF THESE COMPOUNDS AS MEDICINES.
AR006678A1 (en) DERIVATIVES OF TRICYCLIC MACROLIDES, A PHARMACEUTICAL COMPOSITION THAT CONTAINS THEM, USE OF THEM TO PREPARE MEDICINES AND PROCEDURE FOR THEIR PREPARATION
ECSP088404A (en) NEW IMIDAZO DERIVATIVES [4,5-B] PIRIDINE AS INHIBITORS OF THE GLUCÓGENO SINTASA QUINASA 3, FOR USE IN THE TREATMENT OF DEMENTIA AND NEURODEGENERATIVE DISORDERS
FI802404A (en) FREQUENCY REQUIREMENT FOR THERAPEUTIC ACTIVATION OF ACTIVE HETEROCYCLIS
AR037517A1 (en) DERIVATIVES OF NAFTIRIDINES, A PROCESS FOR THE PREPARATION, PHARMACEUTICAL COMPOSITION AND THE USE OF THEM FOR THE PREPARATION OF A MEDICINAL PRODUCT FOR THE TREATMENT OF AN INFLAMMATORY DISEASE
EA200400664A1 (en) PHARMACEUTICAL COMPOSITIONS, INCLUDING METHFORMIN AND GLIBENCLAMIDE, APPLIED TO THE TREATMENT OF TYPE II DIABETES
HUP0401192A2 (en) Use of photosenzitizing agent for preparation ot, of pharmaceutical composition for treating wounds
PA8432901A1 (en) PIRIDILPIRROL COMPOUNDS
BR9813651A (en) Antipicornoviral compounds and methods for their use and preparation
SE0100569D0 (en) New compounds
ES2147320T3 (en) DERIVATIVES OF N- (3-BENZOFURANIL) UREA.
ATE35136T1 (en) NEW BENZISOSELENAZOLONES, PROCESS FOR THEIR PRODUCTION AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM.
BRPI0410391A (en) (2-Hydroxy-2- (4-hydroxy-3-hydroxymethylphenyl) ethylamino) propylphenyl derivatives as beta2 agonists
SE0102055D0 (en) New Compounds
BR0315958A (en) Compound, pharmaceutical composition, process for preparing a compound, new intermediates and use of the compound
AR001769A1 (en) Benzamide enterokinetics pharmaceutical compositions containing them, a process for the preparation of said pharmaceutical compositions, the use of said compounds for the manufacture of medicines and a process for their preparation.
ES2115220T3 (en) NEW USE OF BIS-HETERO-CYCLIC COMPOUNDS AS ANTI-INFLAMMATORY AGENTS AND PHARMACEUTICAL COMPOSITIONS THEREOF.
ATE288919T1 (en) THIAZOLOPYRIMIDINES AND THEIR USE AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY
IT1255704B (en) HETEROCYCLIC AMINES USEFUL IN THERAPY OF ASTHMA AND AIRWAY INFLAMMATION
NO20055754L (en) Kolkisosidanaloger
HRP20050831A2 (en) Novel oxazole derivatives, their manufacture and use as pharmaceutical agents